What is the MOA of latanoprostene bunod 0.024% (Vyzulta)?

Unlock all questions

This demo includes only 20 questions. Upgrade to access hundreds of questions, flashcards, exam simulations, and disable ads.

Full question bankExam simulationsFlashcards
From $25.99Unlock all

Boost your readiness for the Primary Open-Angle Glaucoma Test. Utilize flashcards and multiple-choice questions complete with hints and detailed explanations to enhance your understanding.

Multiple Choice

What is the MOA of latanoprostene bunod 0.024% (Vyzulta)?

Explanation:
Latanoprostene bunod lowers IOP by increasing outflow through two pathways: it uses the prostaglandin F2α–like component to boost uveoscleral outflow, and it includes a nitric oxide donor that relaxes the trabecular meshwork and Schlemm’s canal to enhance conventional outflow. This dual mechanism—increasing both uveoscleral and trabecular outflow—is what makes it effective. The correct statement captures this combined action from the PGA part and the NO-donor part. It does not primarily work by increasing trabecular resistance, inhibiting carbonic anhydrase, or reducing aqueous production.

Latanoprostene bunod lowers IOP by increasing outflow through two pathways: it uses the prostaglandin F2α–like component to boost uveoscleral outflow, and it includes a nitric oxide donor that relaxes the trabecular meshwork and Schlemm’s canal to enhance conventional outflow. This dual mechanism—increasing both uveoscleral and trabecular outflow—is what makes it effective. The correct statement captures this combined action from the PGA part and the NO-donor part. It does not primarily work by increasing trabecular resistance, inhibiting carbonic anhydrase, or reducing aqueous production.

More Multiple Choice Questions
Subscribe

Get the latest from Passetra

You can unsubscribe at any time. Read our privacy policy